• Sirius Therapeutics

  Participated · Series B · May 2025

  Sirius Therapeutics is developing siRNA therapeutics targeting cardiometabolic disorders and next-generation RNA delivery technologies. The company has three clinical-stage programs and a deep preclinical pipeline. Its lead candidate, SRSD107, is a long‑acting anticoagulant poised to begin Phase 2 clinical development in Europe, with an application submitted to the EMA. SRSD216 has begun Phase 1 studies after receiving U.S. FDA and China NMPA approvals for trials in hyperlipoproteinemia in patients with atherosclerotic cardiovascular disease. SRSD101 is undergoing Phase 1 clinical trials in China. Sirius plans to use the new financing to advance clinical programs and expand its pipeline globally.

• Odyssey Therapeutics

  Participated · Series C · Dec 2023

  Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing medicines designed to precisely target disease pathology in autoimmune and inflammatory diseases. Since its founding in 2021, the company has built comprehensive drug discovery and development capabilities and advanced an internally discovered program through multiple clinical milestones. Odyssey has nominated multiple development candidates and established collaborations with pharmaceutical leaders and biotech innovators. Its portfolio includes internally discovered clinical and preclinical candidates intended to induce deep and durable remission across several inflammatory diseases with unmet need. The company plans to advance these programs toward important clinical milestones and translate scientific efforts into patient benefit. Odyssey recently completed a major financing to support progression of its clinical pipeline. Odyssey Therapeutics has built a discovery and development platform that merges computational and experimental technologies to identify modality-agnostic drug targets with high clinical potential. From its Boston headquarters, the company has advanced multiple programs from ideation to a portfolio of high-value product candidates within about two years of founding in late 2021. Odyssey is focused on bringing immunology and oncology therapeutics into clinical development, with several molecules that could enter the clinic in the next 12 months. Proceeds from financing will support advancement of multiple programs into clinical studies and continued investment in discovery to build a sustainable model for therapeutic innovation. The company emphasizes a capital-efficient model and aims to deliver safe and effective precision medicines to patients with serious diseases. Leadership includes founder and CEO Gary D. Glick, Ph.D., and an experienced board guiding clinical and company-building strategy. Odyssey Therapeutics, based in Boston, raised $168M in a Series B funding round led by General Catalyst. The round included participation from Fidelity Management & Research Company, T. Rowe Price Associates, GreatPoint Ventures, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, The Healthcare Innovation Investment Fund LLC, OrbiMed, SR One, Foresite Capital, Logos Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures and Creacion Ventures. The company intends to use the funds to advance its portfolio of precision immunomodulators and oncology medicines. Its immunology and oncology portfolio encompasses eight declared programs initially focused on small molecule and protein therapeutics. Odyssey is building a discovery engine that integrates artificial intelligence and machine learning for molecular design, a chemistry platform encompassing proprietary covalent libraries targeting multiple amino acids, molecular glues and natural products, and a functional genomics platform for novel target discovery. Gary D. Glick, Ph.D. is Founder and Chief Executive Officer. Odyssey Therapeutics develops next-generation precision immunomodulators and oncology medicines using a discovery platform that combines target biology, medicinal and structural chemistry, physics-based molecular simulations, and AI/machine learning. The company was founded by Gary D. Glick, Ph.D., and is led by a team with a track record that includes helping bring more than 20 drugs to market. Odyssey intends to advance multiple pipeline programs and expand its discovery platform to broaden the druggable genome. Financially, the company completed a large Series A financing (see deal details). Odyssey is headquartered in Boston, with labs there, and is expanding its team to more than 90 scientists and staff. The company emphasizes selecting targets and therapeutic modalities aimed at maximizing clinical impact.

• Larkspur Biosciences

  Participated · Equity · May 2023

  Larkspur Biosciences develops precision cancer immunotherapies using its proprietary LarkX platform, which leverages patient genetics, immune phenotypes, bioinformatics, and complex in vitro models to discover immune-evasion signatures. Its lead programs include an approach to lipid remodeling intended to uncloak tumors and a program targeting Pin1, a mechanism of fibroblast differentiation to activate immune cells. The company’s initial clinical strategy targets a genetically- and immunologically-characterized subtype of colorectal cancer whose patients have T cells at the tumor and can be identified via biopsy. Larkspur positions these insights as applicable across multiple cancer indications that share evasion signatures. The company is led by CEO Catherine Sabatos-Peyton and was founded by Drs. Lewis Cantley, Nathanael Gray, and Vijay K. Kuchroo. It raised financing to advance IND-enabling studies and further ongoing preclinical work.

• Frontera Therapeutics

  Participated · Series B · Jul 2022

  Frontera Therapeutics is a global, fully-integrated, clinical-stage biotechnology company leveraging its APEX Technology & Manufacturing platform to develop and manufacture gene therapy candidates across multiple disease areas. The company's core approach is an innovative adeno-associated virus (AAV) gene expression system designed to optimize new and clinically validated AAV vectors to improve safety and efficacy. Frontera maintains in-house GMP manufacturing capabilities to enable rapid production across the product lifecycle and advance AAV therapies from research to clinical development. Its development pipeline spans orphan diseases and larger patient markets, including ophthalmology, hematology, neurology, and metabolic diseases. In July 2022 the company closed a $160M Series B financing. The FDA has accepted the company's IND to initiate a first-in-human trial of FT-001, a gene therapy candidate for a rare genetic retinal disease that leads to severe vision loss.

• MOMA Therapeutics

  Participated · Series B · May 2022

  MOMA Therapeutics discovers precision medicines by targeting molecular machines that underlie human disease, focusing on vulnerabilities tied to stepwise protein conformational changes. The company combines advances in biochemistry, biophysics, structural biology, chemistry and functional genomics to build its drug discovery platform. It has generated multiple oncology programs and aims to develop high-impact precision oncology medicines for patients with unmet medical needs. Proceeds from the recent financing will be used to further develop product opportunities and advance a rich pipeline of precision oncology programs toward the clinic. Launched in 2020, MOMA has bolstered its team and is financed by a group of prominent life sciences investors. The company is based in Cambridge, Mass., and has continued to expand its board and investor syndicate as it progresses its programs.

No current team members are available.